Tenapanor for the treatment of irritable bowel syndrome with constipation

References

• Sinagra E, Romano C, Cottone M. Psychopharmacological treatment and psychological interventions in irritable bowel syndrome. Gastroenterol Res Pract. 2012;2012:486067. [PMID: 22956940].
   PubMed Web of Science ®Google Scholar
• Sinagra E, Morreale GC, Mohammadian G, et al. New therapeutic perspectives in irritable bowel syndrome: targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond. World J Gastroenterol. 2017 Sep 28;23(36):6593–6627. Review. PubMed PMID: 29085207; PubMed Central PMCID: PMC5643283.
   PubMed Web of Science ®Google Scholar
• Endo Y, Shoji T, Fukudo S. Epidemiology of irritable bowel syndrome. Ann Gastroenterol. 2015 Apr-Jun;28(2):158–159. PubMed PMID: 25830818; PubMed Central PMCID: PMC4367204.
   PubMed Web of Science ®Google Scholar
• Thompson WG. A world view of IBS. In: Spiller R, Camilleri M, editors. The irritable bowel syndrome. Diagnosis and treatment. 1 ed. Orlando: WB Saunders; 2002. p. 17–26.
   Google Scholar
• Saito YA, Schoenfeld P, Locke GRI. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol. 2002;97:1910–1915.
   PubMed Web of Science ®Google Scholar
• Kanazawa M, Endo Y, Whitehead WE, et al. Patients and non-consulters with irritable bowel syndrome reporting a parental history of bowel problems have more impaired psychosocial distress. Dig Dis Sci. 2004;49:1046–1053.
   PubMed Web of Science ®Google Scholar
• Miwa H. Prevalence of irritable bowel syndrome in Japan: internet survey using Rome III criteria. Patient Prefer Adherence. 2008;2:143–147.
   PubMedGoogle Scholar
• Lau EM, Chan FK, Ziea ET, et al. Epidemiology of irritable bowel syndrome in Chinese. Dig Dis Sci. 2002;47:2621–2624.
   PubMed Web of Science ®Google Scholar
• Waehrens R, Ohlsson H, Sundquist J, et al. Low prevalence of irritable bowel syndrome in primary health care in four Swedish counties. Scand J Prim Health Care. 2013 Sep;31(3):132–137.
   PubMed Web of Science ®Google Scholar
• Enck P, Aziz Q, Barbara G, et al. Irritable bowel syndrome. Nat Rev Dis Primers. 2016;2:16014. [PMID: 27159638]. .
   PubMed Web of Science ®Google Scholar
• Layer P, Andresen V, Diemert S, et al. Economic Burden and Quality of Life of Moderate-To-Severe Irritable Bowel Syndrome With Constipation (Ibs-C) In Germany: results From The Ibis-C Study. Value Health. Mackinnon J, Bertsch J, Fortea J, Tack J. 2015;18:A624. [PMID: 26533504]. .
   PubMed Web of Science ®Google Scholar
• Mulak A, Taché Y. Sex difference in irritable bowel syndrome: do gonadal hormones play a role? Gastroenterol Pol. 2010;17:89–97. [PMID: 25435761].
   PubMedGoogle Scholar
• Heitkemper M, Jarrett M, Bond EF, et al. Impact of sex and gender on irritable bowel syndrome. Biol Res Nurs. 2003;5:56–65. [PMID: 12886671].
   PubMedGoogle Scholar
• Mearin F, Lacy BE, Chang L, et al. Bowel Disorders. Gastroenterology. 2016. Epub ahead of print [PMID: 27144627]. DOI:10.1053/j.gastro.2016.02.031.
   Web of Science ®Google Scholar
• Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997;32:920–924. [PMID: 9299672].
   PubMed Web of Science ®Google Scholar
• El-Salhy M, Gundersen D, Hatlebakk JG, et al. Irritable bowel syndrome: diagnosis, pathogenesis and treatment options. New York: Nova Science Publishers, Inc.; 2012.
   Google Scholar
• El-Salhy M, Gundersen D, Gilja OH, et al. Is irritable bowel syndrome an organic disorder? World J Gastroenterol. 2014;20:384–400. [PMID: 24574708]. .
   PubMed Web of Science ®Google Scholar
• Jadallah KA, Kullab SM, Sanders DS. Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies. World J Gastroenterol. 2014 Jul 21;20(27):8898–8909. Review. PubMed PMID: 25083062; PubMed Central PMCID: PMC4112860. .
   PubMed Web of Science ®Google Scholar
• Hungin AP, Whorwell PJ, Tack J, et al. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther. 2003;17:643–650.
   PubMed Web of Science ®Google Scholar
• Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol. 2009;104(Suppl 1):S1–S35.
   PubMed Web of Science ®Google Scholar
• DiBonaventura M, Sun SX, Bolge SC, et al. Health-related quality of life, work productivity and health care resource use associated with constipation predominant irritable bowel syndrome. Curr Med Res Opin. 2011;27:2213–2222.
   PubMed Web of Science ®Google Scholar
• Dibonaventura MD, Prior M, Prieto P, et al. Burden of constipation-predominant irritable bowel syndrome (IBS-C) in France, Italy, and the United Kingdom. Clin Exp Gastroenterol. 2012;5:203–212.
   PubMedGoogle Scholar
• Fortea J, Prior M. Irritable bowel syndrome with constipation: a European-focused systematic literature review of disease burden. J Med Econ. 2013;16:329–341.
   PubMedGoogle Scholar
• Camilleri M, Tack JF. Current medical treatments of dyspepsia and irritable bowel syndrome. Gastroenterol Clin North Am. 2010;39:481–493.
   PubMed Web of Science ®Google Scholar
• Hulisz D. The burden of illness of irritable bowel syndrome: current challenges and hope for the future. J Manag Care Pharm. 2004;10:299–309.
   PubMedGoogle Scholar
• Camilleri M, Andresen V. Current and novel therapeutic options for irritable bowel syndrome management. Dig Liver Dis. 2009;41:854–862.
   PubMedGoogle Scholar
• Therapeutics K. Knight announces exclusive license agreement with Ardelyx for tenapanor [media release]. [cited 2018 Mar 19]. Available from: http://www.gudknight.com
   Google Scholar
• Markham A. Tenapanor: first Approval. Drugs. 2019 Nov;79(17):1897–1903. 10.1007/s40265-019-01215-9. Review. PubMed PMID: 31677150.
   PubMed Web of Science ®Google Scholar
• Ardelyx.com [Internet]. Ardelyx and Knight collaborate to bring tenapanor to patients in Canada [media release]. cited 2018 Mar 19. Available from: http://www.ardelyx.com
   Google Scholar
• Block GA, Rosenbaum DP, Leonsson-Zachrisson M, et al. Effect of tenapanor on serum phosphate in patients receiving hemodialysis. J Am Soc Nephrol. 2017;28(6):1933–1942.
   PubMed Web of Science ®Google Scholar
• Lembo A, Chey WD, Rosenbaum DP. An open label long-term safety trial (T3MPO-3) of tenapanor in patients With irritable bowel syndrome with constipation (IBS-C) [abstract no. 430 and poster P0338]. Am J Gastroenterol. 2018;113(Suppl):S252.
   Google Scholar
• Ardelyx.com [Internet]. IBSRELA (tenapanor) tablets, for oral use: US prescribing information. 2019. cited 2019 Oct 22. Available from https://www.acces sdata.fda.gov/drugs atfda_docs/label/2019/21180 1s000 lbl.pdf
   Google Scholar
• Spencer AG, Jacobs JW, Leadbetter MR, et al. RDX5791, a first-in-class minimally systemic NHE3 inhibitor in clinical development for CIC and IBSC, increases intestinal sodium leading to enhanced intestinal fluid volume and transit. Gastroenterology. Proceedings of the Drug Disease Week 2011, Chicago. 2011;140:S–99.
   Web of Science ®Google Scholar
• Johansson S, Rosenbaum DP, Ahlqvist M, et al. Effects of tenapanor on cytochrome P450-mediated drug-drug interactions. Clin Pharmacol Drug Dev. 2017;6(5):466–475.
   PubMed Web of Science ®Google Scholar
• Zielińska M, Wasilewski A, Fichna J. Tenapanor hydrochloride for the treatment of constipation-predominant irritable bowel syndrome. Expert Opin Investig Drugs. 2015;24(8):1093–1099. Epub 2015 Jun 12. Review. PubMed PMID: 26065434.
   PubMedGoogle Scholar
• Spencer AG, Labonte ED, Rosenbaum DP, et al. Intestinal inhibition of the Na+/H+ exchanger 3 prevents cardiorenal damage in rats and inhibits Na+ uptake in humans. Sci Transl Med. 2014;6(227):227ra36.
   PubMed Web of Science ®Google Scholar
• Eutamene E, Charmot D, Navre M, et al. Visceral Antinociceptive Effects of RDX5791, a First-in-Class Minimally Systemic NHE3 Inhibitor on Stress- Induced Colorectal Hypersensitivity to Distension in Rats. Gastroenterology. Proceedings of the DDW meeting 2011, Chicago IL. 2015;140:S-57-8.
   Google Scholar
• Li Q, King AJ, Liu L, et al. Tenapanor reduces IBS pain through inhibition of TRPV1-dependent neuronal hyperexcitability in vivo [abstract no. 484 and poster P2027]. Am J Gastroenterol. 2017;112(Suppl.1):S255.
   Google Scholar
• Rosenbaum DP, Yan A, Jacobs JW. Pharmacodynamics, safety, and tolerability of the NHE3 inhibitor tenapanor: two trials in healthy volunteers. Clin Drug Investig. 2018;38(4):341–351.
   PubMed Web of Science ®Google Scholar
• King AJ, Siegel M, He Y, et al. Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability. Sci Transl Med. 2018;10(456):1–17.
   Web of Science ®Google Scholar
• Rosenbaum DP The efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C). ClinicalTrials.gov Identifier: NCT01923428. 2014
   Google Scholar
• Chey WD, Lembo AJ, Korner P, et al. Efficacy and safety of tenapanor in patients with constipation predominant irritable bowel syndrome: a 12-week, double-blind, placebo-controlled, randomized phase 3 trial [abstract no. 421]. Am J Gastroenterol. 2017;112(Suppl. 1):S226–S7.
   Google Scholar
• Chey WD, Lembo AJ, Yan A, et al. Efficacy and safety of tenapanor in patients with constipation predominant irritable bowel syndrome: a 6-month, double-blind, placebo-controlled phase 3 trial (T3mpo-2) [abstract no. 885]. Gastroenterology. 2018;154(6 Suppl. 1):S–1362.
   Web of Science ®Google Scholar
• Black CJ, Burr NE, Quigley EMM, et al. Efficacy of Secretagogues in Patients With Irritable Bowel Syndrome With Constipation: systematic Review and Network Meta-analysis. Gastroenterology. 2018 Dec;155(6):1753–1763.
   PubMed Web of Science ®Google Scholar
• Shah ED, Kim HM, Schoenfeld P. Efficacy and Tolerability of Guanylate Cyclase-C Agonists for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2018 Mar;113(3):329–338.
   PubMed Web of Science ®Google Scholar
• Block GA, Rosenbaum DP, Yan A, et al. Efficacy and safety of tenapanor in patients with hyperphosphatemia receiving maintenance hemodialysis: a randomized phase 3 trial. J Am Soc Nephrol. 2019;30(4):641–652.
   PubMed Web of Science ®Google Scholar
• Ardelyx.com [Internet]. Ardelyx announces positive results from the pivotal phase 3 AMPLIFY study evaluating tenapanor in dialysis patients who have uncontrolled hyperphosphatemia despite phosphate binder treatment cited 2019 Sep 3. Available from: http://www.ardelyx.com
   Google Scholar